ARDS Clinical Trials
Here are the 6 most popular medical studies for ards
Surfactant
Surfactant Therapy for Neonatal Respiratory Distress Syndrome
This trial studies preterm babies w/respiratory distress syndrome, randomized to either Curosurf or Infasurf to see which works best. Exclusions: Congenital anomalies, other causes of distress, & emergent intubation. Parental consent required.
Device
CNEP + HFNC for Respiratory Insufficiency
This trial is testing a breathing support device to see if it can improve breathing in patients with lung injury. The device uses a plastic shell and vacuum to help the chest expand with breathing. Results will show if it can help those with acute hypoxemic respiratory failure.
Mesenchymal Stem Cell
Cord Blood-Derived Mesenchymal Stem Cells for Blood Cancers
This trial will test whether it is feasible to use cord blood-derived mesenchymal stem cells (MSCs) to treat patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection. If it is successful, a larger trial will be conducted to compare the effect of MSCs with standard of care in these patients.
Anti-metabolites
Decitabine for COVID-19
This trial is testing if the leukemia drug decitabine can help people with severe COVID-19. 40 people will be enrolled, half receiving decitabine and half receiving a placebo. The primary objective is to determine if decitabine is safe and effective for COVID-19 ARDS.
Popular filter options for ards trials
ARDS Clinical Trials
View 33 ARDS medical studies.
Procedure
PEEP Strategies for ARDS
This trial is testing two different ways of setting the level of positive end-expiratory pressure (PEEP) in people with acute respiratory distress syndrome (ARDS), to see which one results in better lung function and heart function.
Procedure
Ventilation Strategy for Acute Respiratory Distress Syndrome
This trial is examining if setting the ventilator based on measurements of respiratory mechanics can help to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS), in both COVID-19 and non-COVID-19 patients.
Respiratory Distress Syndrome Clinical Trials
View 12 Respiratory Distress Syndrome medical studies.
Non-Invasive Spinal Cord Stimulation for Respiratory Distress Syndrome
This trial will test if non-invasive spinal cord stimulation can help prevent respiratory muscle atrophy in ARDS patients on mechanical ventilation. 10 elective surgery & 10 ARDS patients will be tested with a Restore Technology stimulator.
Procedure
LISA for Premature Birth
This trial is testing whether or not using LISA in the delivery room decreases the intubation rates in preterm infants at 23-25 weeks gestational age, during first 72 hours compared to the standard approach of stabilization on nasal CPAP in the DR.
Phase 3 Acute Respiratory Distress Syndrome Clinical Trials
View 47 phase 3 acute respiratory distress syndrome medical studies.
Mechanical Ventilation
Ventilation Strategies for Neonatal Respiratory Distress Syndrome
This trial compares two different breathing strategies for preterm infants with respiratory distress. The goal is to see if a faster breathing rate will help them avoid complications like ventilator-induced lung injury.
Monoclonal Antibodies
EB05 for Hospitalized COVID-19 Patients
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Acute Respiratory Distress Syndrome Clinical Trials With No Placebo
View 47 acute respiratory distress syndrome medical studies that do not have a placebo group.
Non-Invasive Spinal Cord Stimulation for Respiratory Distress Syndrome
This trial will test if non-invasive spinal cord stimulation can help prevent respiratory muscle atrophy in ARDS patients on mechanical ventilation. 10 elective surgery & 10 ARDS patients will be tested with a Restore Technology stimulator.
Procedure
LISA for Premature Birth
This trial is testing whether or not using LISA in the delivery room decreases the intubation rates in preterm infants at 23-25 weeks gestational age, during first 72 hours compared to the standard approach of stabilization on nasal CPAP in the DR.
View More Ards Trials
See another 25 medical studies focused on ards.
Frequently Asked Questions
Introduction to ards
What are the top hospitals conducting ards research?
When it comes to advancing treatments for Acute Respiratory Distress Syndrome (ARDS), several top hospitals are leading the way. In Boston, Brigham and Women's Hospital stands out with three active ARDS trials and a total of 13 trials dedicated to this condition. Since recording their first trial in 2012, they have been at the forefront of research into this life-threatening lung disorder. Meanwhile, on the West Coast, Sharp Mary Birch Hospital for Women & Newborns in San Diego has made significant contributions as well. This hospital is currently conducting two active ARDS trials, adding to their five previously completed studies since starting their first trial in 2017.
In Birmingham, Alabama, the University of Alabama at Birmingham is also playing a crucial role in ARDS research. With two ongoing clinical trials focused on this condition and an impressive history of 13 completed trials dating back to their inaugural investigation in 1998, they continue to push boundaries and seek innovative solutions. Back in Boston, Massachusetts General Hospital joins the ranks with two current ARDS trials and an outstanding record of conducting 17 previous studies since initiating their first trial back in 1994.
Finally taking its place among these notable institutions is Weill Cornell Medical College located in New york City where cutting-edge research into ARDS is thriving. They are actively involved with two ongoing clinical trials while having recorded only three previous investigations so far; however theirs can be traced back quite recently - commencing groundbreaking work specifically tailored around ards cases merely from year nineteen onwards within twenty-first century being marked by rigorous scientific exploration into this realm.
These esteemed hospitals represent not only hope for those affected by ARDS but also groundbreaking advancements that impact patients worldwide struggling with respiratory distress conditions such as pneumonia or sepsis-related complications which can lead individuals facing critical health challenges ahead- proving significance United States healthcare system holds towards tirelessly developing new therapies ensuring improved outcomes across globe
Which are the best cities for ards clinical trials?
When it comes to ARDS clinical trials, several cities emerge as leading hubs for research and development. Boston, Massachusetts boasts 8 active trials exploring various interventions such as teleconsultation groups and inhaled carbon monoxide at different doses. Durham, North carolina follows closely with 4 ongoing studies investigating treatments like budesonide and personalized dose inhalation of carbon monoxide. New york City also showcases 4 active trials focusing on respiratory mechanics and innovative approaches like high flow nasal cannula combined with continuous negative extrathoracic pressure. Birmingham, Alabama and Houston, Texas both contribute to the field with their respective set of ongoing trials involving budesonide and mesenchymal stem cells. These cities provide individuals diagnosed with ARDS access to cutting-edge clinical trials that pave the way for advancements in care and offer hope for better outcomes.
Which are the top treatments for ards being explored in clinical trials?
In the realm of clinical trials for ARDS, several potential treatments are currently under examination. Leading the pack is EV-Pureâ„¢ and WJ-Pureâ„¢, with one active trial and being first listed in 2023. Following closely behind is LISA, also with one active trial but having made its debut in 2020. Additionally, budesonide (Pulmicort nebulizing suspension) has shown promise with one ongoing trial since its introduction to the field in 2021. These pioneering treatments offer hope for finding new approaches to combat ARDS and improve outcomes for patients affected by this challenging condition.
What are the most recent clinical trials for ards?
Recent clinical trials for acute respiratory distress syndrome (ARDS) offer promising advancements in treatment options. One such trial explores the use of MSC-exosomes, administered intravenously every other day on an escalating dose, to address ARDS effectively. Another study focuses on inhaled carbon monoxide at personalized doses determined by CFK equation, aiming to achieve a specific COHb level. Additionally, GEn-1124 and EV-Pureâ„¢ and WJ-Pureâ„¢ are being investigated in separate trials as potential treatments for ARDS. These developments bring hope for improved outcomes and enhanced care for individuals grappling with this challenging condition.
What ards clinical trials were recently completed?
Several recent clinical trials have made strides in the field of Acute Respiratory Distress Syndrome (ARDS), shedding light on potential breakthrough treatments. Notably, Immunovative Therapies successfully completed a trial investigating AlloStim in July 2021. Similarly, Baylor College of Medicine concluded their study on Mesenchymal Stromal Cells earlier that year in February 2021. Additionally, Windtree Therapeutics achieved an important milestone by completing their Lucinactant trial in January 2021. Although not as recent, The University of Texas Health Science Center wrapped up their vadadustat trial in August 2020. These accomplishments provide valuable insights into innovative approaches for ARDS treatment and offer hope to patients affected by this challenging condition.